Fig. 4: In vivo efficacy of the representative AMPs from primitive commensal S. copri against S. aureus 6538 and P. aeruginosa 27853. | Nature Communications

Fig. 4: In vivo efficacy of the representative AMPs from primitive commensal S. copri against S. aureus 6538 and P. aeruginosa 27853.

From: Identification of antimicrobial peptides from ancient gut microbiomes

Fig. 4: In vivo efficacy of the representative AMPs from primitive commensal S. copri against S. aureus 6538 and P. aeruginosa 27853.

a The experimental design for assessing in vivo treatment effectiveness by AMPs from S. copri. b Experimental confirmation of pathogens infection load in control, vancomycin/polymxin B, and AMP8, AMP13, AMP30, AMP31, and AMP38 treatment groups by streaking on LB agar plates. c Representative in vivo wound healing results by negative control PBS, AMP groups, and positive control vancomycin or polymyxin B at the same dosage in vivo. d The representative histological results of mice wound tissues from groups of control, vancomycin/polymxin B, AMP8, AMP13, AMP30, AMP31, and AMP38 generated using H&E and Masson staining protocols. BioRender was used during the construction of the Figure, with the issued License agreement number GG294KREHV (Created in BioRender. Chen, S. (2025) https://BioRender.com/7b397jf).

Back to article page